Celltrion to Announce Phase 2 Clinical Trial Results of COVID-19 Antibody Treatment on the 13th

[Asia Economy Reporter Cho Hyun-ui] The results of the Phase 2 clinical trial of Celltrion's novel coronavirus disease (COVID-19) antibody treatment 'Rekkironaju' will be disclosed for the first time on the 13th.

According to the pharmaceutical and bio industry on the 5th, Celltrion will participate in the 2021 High1 New Drug Development Symposium hosted by the Korean Pharmaceutical Society on the 13th of this month and present the global Phase 2 clinical trial results of Rekkironaju.

Earlier, after completing the global Phase 2 clinical trial of Rekkironaju, Celltrion applied for conditional approval to the Ministry of Food and Drug Safety (MFDS) on the 29th of last month. At that time, considering the public's keen interest in COVID-19 treatments, the MFDS requested and agreed to keep detailed clinical data confidential until separate guidelines are issued.

However, as concerns grew that clear clinical results remained elusive despite the imminent introduction of a domestic COVID-19 treatment, an early disclosure was decided. Celltrion recently obtained consent from the MFDS for early release of clinical data and will present the Phase 2 clinical trial results at this symposium, where it can participate first.

Celltrion also plans to announce the Phase 2 clinical trial results of Rekkironaju soon at international conferences.